Pulse Wave Velocity in Atherosclerosis

Early detection of subclinical atherosclerosis is important to reduce patients' cardiovascular risk. However, current diagnostic strategy focusing on traditional risk factors or using risk scoring is not satisfactory. Non-invasive imaging tools also have limitations such as cost, time, radiatio...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in cardiovascular medicine Vol. 6; p. 41
Main Authors Kim, Hack-Lyoung, Kim, Sang-Hyun
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 09.04.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Early detection of subclinical atherosclerosis is important to reduce patients' cardiovascular risk. However, current diagnostic strategy focusing on traditional risk factors or using risk scoring is not satisfactory. Non-invasive imaging tools also have limitations such as cost, time, radiation hazard, renal toxicity, and requirement for specialized techniques or instruments. There is a close interaction between arterial stiffness and atherosclerosis. Increased luminal pressure and shear stress by arterial stiffening causes endothelial dysfunction, accelerates the formation of atheroma, and stimulates excessive collagen production and deposition in the arterial wall, leading to the progression of atherosclerosis. Pulse wave velocity (PWV), the most widely used measure of arterial stiffness, has emerged as a useful tool for the diagnosis and risk stratification of cardiovascular disease (CVD). The measurement of PWV is simple, non-invasive, and reproducible. There have been many clinical studies and meta-analyses showing the association between PWV and coronary/cerebral/carotid atherosclerosis. More importantly, longitudinal studies have shown that PWV is a significant risk factor for future CVD independent of well-known cardiovascular risk factors. The measurement of PWV may be a useful tool to select subjects at high risk of developing subclinical atherosclerosis or CVD especially in mass screening.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Ailin Barseghian, University of California, Irvine, United States
Reviewed by: Teresa Padro, Sant Pau Institute for Biomedical Research, Spain; Jürgen Bernhagen, Ludwig Maximilian University of Munich, Germany
This article was submitted to Cardiovascular Epidemiology and Prevention, a section of the journal Frontiers in Cardiovascular Medicine
ISSN:2297-055X
2297-055X
DOI:10.3389/fcvm.2019.00041